Skip to main content

Table 1 Demographics data and seroprevalence of hepatitis B virus (HBV) markers and titers

From: Hepatitis B virus vaccination booster does not provide additional protection in adolescents: a cross-sectional school-based study

Age group 6 y/o 12 y/o 15 y/o 18 y/o 6-12 y/o 15-18 y/o
Item (n = 524) (n = 450) (n = 1464) (n = 4512) (n = 974) (n = 5976)
Gender       
  Male, n (%) 299(57.1) 205(45.6) 740(50.5) 1657(36.7) 504(51.7) 2397(40.1)
  Female, n (%) 225(42.9) 245(54.4) 724(49.5) 2855(63.3) 470(48.3) 3579(59.9)
Age (Mean ± SD, yr) 6.5 ± 0.3 12.5 ± 0.3 15.5 ± 0.5 18.7 ± 0.7 9.3 ± 3.0 17.9 ± 1.5
Anti-HBs (+), n 332 142 574 2033 474 2607
(%, 95% CI) (63.4, 59.3-67.5) (31.6, 27.3-35.9) (39.2, 36.7-41.7) (45.1, 43.6-46.6) (48.7, 45.6-51.8) (43.6, 42.3-44.9)
Anti-HBs (−), n 192 308 890 2479 500 3369
(%, 95% CI) (36.6, 32.5-40.7) (68.4, 64.1-72.7) (60.8, 58.3-63.3) (54.9, 53.4-56.4) (51.3, 48.2-54.4) (56.4, 55.1-57.7)
  P-value <0.001* 0.003*
Anti-HBs median titer 21.2 NA 3.9 4.8 21.2 4.6
  P-value <0.001* <0.001*
HBsAg (+), n 1 7 16 56 8 72
(%, 95% CI) (0.2, 0.0-0.6) (1.6, 0.4-2.8) (1.1, 0.6-1.6) (1.2, 0.9-1.5) (0.8, 0.2-1.4) (1.2, 0.9-1.5)
HBsAg (−), n 523 443 1448 4456 966 5904
(%, 95% CI) (99.8, 99.4-100.0) (98.4, 97.2-99.6) (98.9, 98.4-99.4) (98.8, 98.5-99.1) (99.2, 98.6-99.8) (98.8, 98.5-99.1)
  P-value 0.154 0.336
  1. Note: Anti-HBs, antibody to HBV surface antigen; HBsAg, HBV surface antigen; y/o, year old; NA, not available; 95% CI, 95% confidence interval; Data are presented as or n and percentage.
  2. *p-value < 0.05 was considered statistically significant after test.